{"id":"W4411037230","doi":"10.1038/s41591-025-03725-4","title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Jewish General Hospital","funders":"Genentech; Japanese Society of Medical Oncology; Eisai; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Natera; Les Laboratories Pierre Fabre; Teva Pharmaceutical Industries; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; F. Hoffmann-La Roche; Vifor Pharma; Chugai Pharmaceutical; Seagen; OncoSec Medical; Roche; Amgen; Pfizer; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Atezolizumab; Breast cancer; Randomized controlled trial; Medicine; Stage (stratigraphy); Oncology; Triple-negative breast cancer; Perioperative; Internal medicine; Peri; Cancer; Surgery; Biology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001202046,0.0003493686,0.00132931,0.0002736175,0.0001804723,0.00003064136,0.0001771814,0.0003475687,0.0004892954],"category_scores_gemma":[0.001652579,0.0001703293,0.0002012998,0.0009345249,0.0008102137,0.00009608611,0.00004773524,0.001166066,0.000001134915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002427414,"about_ca_system_score_gemma":0.0004635015,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01537341,"about_ca_topic_score_gemma":0.00157072,"domain_scores_codex":[0.9973281,0.0005414379,0.0008220504,0.0005333788,0.0004749921,0.0003000381],"domain_scores_gemma":[0.9972858,0.001767746,0.0002544119,0.0003893991,0.000193107,0.0001095658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9621089,0.0001993141,0.0003122035,0.00002316965,0.0008472064,0.00006798514,0.003972379,0.000001011617,0.006018216,0.00005563785,0.00965731,0.01673673],"study_design_scores_gemma":[0.96224,0.0008192391,0.02389415,0.001374446,0.0006911852,0.00001340736,0.001562985,0.0003450047,0.003189693,0.0001172047,0.005575178,0.0001774377],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9123863,0.02251832,0.00004741338,0.0588932,0.001208588,0.002731701,0.0006265021,0.00004111531,0.001546832],"genre_scores_gemma":[0.987389,0.003986681,0.00006233112,0.003826558,0.0009029769,0.0002114253,0.0001486087,0.00001702124,0.003455434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07500264,"threshold_uncertainty_score":0.9911833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03117827596201543,"score_gpt":0.4133979229228024,"score_spread":0.382219646960787,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}